Of Dandelions & Deception: The root that shook the system.

This investigative work is dedicated to my dear friend Nick Adams, taken too soon by cancer, and in honour of the strength of those who continue to fight.

Written by ©https://DarkMatters.Press | 11^th August 2025

Case Summary

The University of Windsor, Canada, found that dandelion root extract could kill cancer cells without harming healthy ones; huge news¹, ², ³. The project was largely funded by local community donors, celebrated in the press, and said to be fast-tracked for human clinical trials⁴. The root extraction method was filed to be patented in 2013 by Dr. Pandey, Dr. Hamm & then PhD student, Ovadje⁵ and was later funnelled into a named corporate entity – Windsor Botanical Therapeutics Inc⁶.

Two years later, with no public news of progression of the trials or development with the corporation, the University affiliated directors of that corporate entity then quietly resigned en masse, leaving Windsor Botanical Therapeutics Inc. to be taken over by two directors with a long line of shell structure supplement companies⁷, ⁸, ⁹, ¹⁰. What happened to this revolutionary natural and evidently non-toxic cancer fighting discovery, and why? I explore these unanswered questions in depth in this fully referenced report.

Funding and Initial Breakthrough

The University of Windsor’s dandelion root research project was primarily community funded through various donors, such as; Seeds4Hope, a local cancer research initiative, with additional support from the Couvillon family, the Knights of Columbus, and the Pajama Angels. The program also gained recognition through a Mitacs Award for Outstanding Innovation, presented to lead researcher Pamela Ovadje for her work on natural anti-cancer agents¹¹.

The project was led by Dr. Siyaram Pandey, a biochemistry professor at the University of Windsor¹², and supported in part by Dr. Caroline Hamm, an oncologist at Windsor Regional Hospital¹³. The research found that dandelion root extract induced apoptosis (programmed cell death) in various cancer cell lines – including melanoma, leukaemia, and pancreatic cancer and colon cancer- without harming healthy cells¹, ¹⁴, ², ³. These results were revolutionary, offering a potential low-toxicity therapeutic approach to hard-to-treat cancers.

The Patent

Following the enormous success of the initial lab-based studies¹,²,¹⁴ the University of Windsor filed a patent to ‘protect’ the intellectual property surrounding the use of dandelion root extract as an anti-cancer agent. The core filing, created in 2013, was titled:

“Medicament Containing Taraxacum Plant Root Extract for Treatment or Prevention of Cancer, and Method for Preparing Same”⁵.

Multiple versions of the patent were filed internationally, including in Canada¹⁵, the United States⁵, and India¹⁶.

The extensive patent (as shown above) consolidates in detail the lab findings, charts, and apoptosis assays demonstrating selective cancer cell death⁵. However, despite its clear therapeutic potential and broad applicability, the patent has seemingly had no commercial traction, no formal product development, and no entry into human clinical trials under university management, contradicting celebratory press reports¹⁷, ¹⁸, ¹⁹.

Instead, Windsor Botanical Therapeutics Inc. – a private startup company would soon take over the trajectory of the dandelion root discovery⁶.

Windsor Botanical Therapeutics Inc. and the Director Exodus

Importantly, the stated reason for founding Windsor Botanical Therapeutics Inc.- as reported in local news coverage – was to carry out human clinical trials that the university could not undertake on its own due to regulatory constraints²⁰. The creation of Windsor Botanical Therapeutics Inc. was portrayed as a crucial step toward testing the safety and efficacy of dandelion root extract in real patients, moving from preclinical promise to licensed therapeutic reality²¹.

Dr. Joseph Elliott: Corporate Oversight or Intellectual Gatekeeping?

Unsurprisingly, Dr. Pandey and Heather Pratt (Executive Director of Research & Innovation at the University of Windsor) became the original directors of Windsor Botanical Therapeutics Inc. in 2016, with Dr. Pandey as designated founder director and Chief Scientific Officer⁶, ¹². However, the early installation of Dr. Joseph Elliott, a seasoned executive deeply entrenched in the biotech and pharmaceutical commercialization²² sphere, as President and CEO of WBT warrants serious scrutiny. His simultaneous ties to the University of Windsor suggest a calculated move – not merely administrative, but potentially strategic. Why would a high-level corporate actor choose to lead a small startup whose only asset was the IP for a promising, natural cancer therapy derived from dandelion root?

The answer may lie not in development, but in containment. Elliott’s abrupt and relatively short-lived presence, followed by the quiet handover to obscure directors²³ resembles a blueprint: install a biotech insider to secure intellectual property, then stall progress while retaining control. Whether he was overseeing a commercialization pathway or a suppression campaign is a matter of informed speculation – but the implications are disturbing either way. Natural remedies very rarely move forward unless they can be patented, monetized, and tightly controlled.

Moreover, the involvement of senior university figures was both formal and visible. On the official University of Windsor staff biographies:

Dr. Pandey is listed as a director of Windsor Botanical Therapeutics, a designation that has remained on his university profile and Journal of Alzheimer’s Disease member profile for many years¹², ²⁴.

Heather Pratt, who held a senior administrative position at the university, also had the Windsor Botanicals Therapeutics directorship listed in visible online profiles²⁵.

Their listed roles as directors of Windsor Botanical Therapeutics Inc. served as a public affirmation of the university’s close involvement in the commercialization effort – suggesting institutional endorsement and oversight of the company’s operations.

However, just two years later in 2018, a significant and sudden shift occurred.

All the original directors, including CSO Sirayan Pandey and designated CEO Joseph Elliot, resigned from the board²³. This marked a pivotal turning point. Following their departure, no explanation was provided publicly, and no progress was released to the public on human clinical trials. A once-promising research-commercialization bridge had effectively gone dark.

The reasons for their resignations were not disclosed in regulatory filings. Instead, WBT’s control quietly transitioned to two new directors; Dr Trajinder and Pramjit Nibber²⁶, ²⁷, ²⁸.

This is where it gets very confusing – and likely, intentionally so.

When searching online for Windsor Botanical Therapeutics Inc. – or even just “Windsor Botanicals” – The only link that appears is a generic e-commerce supplement brand, entirely unrelated to any oncology research²⁹. Retail listings feature liquid collagen, probiotics, melatonin, B12 drops, iron tablets and similar branded wellness products, all marketed as beauty or general health supplements. No dandelion root extract either.

When our investigator emailed Windsor Botanical Therapeutics.com they were told:

“we’re not related to that study – different businesses. We’re part of a larger group of companies now. I can get a message passed along to our CEO for you if you’d like?”

This was their response after asking if they were affiliated with the University of Windsor’s research, and requesting the name of the owner of the business. They would not reveal their corporate ownership, despite our investigator asking directly, and they stopped responding when questioned further; which was odd.

Introducing The Nibbers

Upon closer inspection, Pramjit and Dr Trajinder (or Traj) Nibber, along with Dr Anjan Nibber have been linked to many dissolved or dormant companies over the years, including entities that appear to have been registered primarily to serve as shells³⁰. Some of these UK-based companies list directors with ties to thousands of other businesses – a hallmark of what’s known as “directors-for-hire.” This kind of pattern is not typically associated with companies prioritizing openness or accountability.

The Nibbers most long-standing business enterprise is AOR (under several various slightly differentiated names such as AOR Europe, AOR Inc, AOR Distributions etc in different global registers). On AOR’s research collaborations page, AOR mentions Dr Hamm is collaborating on research partnership involving dandelion root and is in the pre-trial stage³¹.

The Alberta corporate registry shows that AOR Inc. was once registered there, but its status ceased in 2007⁷. No current federal Canadian registration is readily available in public databases, and the active UK registration⁸ raises further questions about where the company is truly based – and under what jurisdiction it operates when selling health products internationally. The lack of clarity around the company’s operational base, combined with its broad claims about international exports (Europe, the U.S., Mexico), raises regulatory concerns – especially given the often-minimal consumer protections across borders.

Transparency? AOR’s Corporate and Ethical Trail

Advanced Orthomolecular Research (AOR) publicly promotes itself as a proudly Canadian company on their Canadian website, emphasizing transparency and scientific integrity. Their branding leans heavily on phrases like “Made in Canada” – a claim clearly intended to inspire trust in both product quality and regulatory oversight³². However, when examined more closely, the company’s corporate history, multi-jurisdictional setup, and shifting affiliations tell a more complicated story.

Genetic Testing and Data Handling: A Trust Us Model?

The concerns deepen when one looks at AOR’s involvement with DNA testing via its “DNA Labs” service³³. AOR’s MyBlueprint privacy pledge offers reassuring language without disclosing the most critical element of genetic testing: the identity of the actual lab performing the DNA analysis. The company assures customers that their genetic information won’t be sold or shared – yet it simultaneously subcontracts multiple external parties in the processing and analysis chain. This creates a data vulnerability chain with little transparency around how data is handled, secured, or potentially repurposed.

When a company tells customers to trust them – while simultaneously operating through multiple opaque legal entities, subcontracting genetic data services, and providing minimal public clarity on regulatory oversight – that is far from transparency.

Windsor Botanical Therapeutics, Inc.: A Familiar Pattern

Now registered to the same individuals tied to AOR, the company presents itself as a continuation of promising university research on dandelion root extract – work originally pioneered by Dr. Siyaram Pandey and supported in part by oncologist Dr. Caroline Hamm. However, since its incorporation, Windsor Botanicals has shown no public-facing activity.

Its existence fits the broader pattern seen across other companies tied to this network: multiple jurisdictions, unclear regulation, limited communication, and inconsistent scientific follow-through.

Several of the companies tied to AOR – including Windsor Botanical Therapeutics Inc. – have a history of late filings, missed deadlines, or prolonged periods of dormancy before basic dissolution⁶, ⁷, ⁹.

Where are They now?

As Windsor Botanical Therapeutics quietly changed hands and the dandelion root cancer therapy research disappeared from public development, many of the individuals once publicly associated with the breakthrough either disappeared from view, shifted roles, or appeared to distance themselves from the original project. What follows is a current snapshot of those once central to the initiative – and how their trajectories may reflect broader questions of erasure, co-optation, and strategic repositioning.

Dr. Pandey

Then: Lead researcher on the dandelion root extract study and listed inventor on the original patents, designated founder director and CSO of Windsor Botanical Therapeutics Inc¹².

Now: Still based at the University of Windsor, listed as a professor in the Department of Chemistry and Biochemistry. Dr Pandey’s department is still receiving frequent donations and funding to discover new cures for cancer and neurological diseases such as Alzheimer’s and Parkinson’s³⁴, ³⁵. However, there is no indication that his current research actively involves dandelion root. Despite his name remaining on early publications, patents and filings, his public role in advancing the research appears dormant.

Dr. Caroline Hamm

Then: Oncologist and co-investigator in the original lab studies; publicly supported the clinical promise of dandelion root and then did a sudden U-turn on the revelations in 2017.

Now: Dr. Caroline Hamm, who was once actively involved in the dandelion root research and is listed on the 2013 filed patent titled “Medicament Containing Taraxacum Plant Root Extract for the Treatment or Prevention of Cancer,”⁵ later gave a seemingly contradictory interview to the Windsor Star in which she described the original findings as “anecdotal” and warned that “anything can be toxic.”³⁶, ³⁷. Dr Hamm suggested she has received copious emails from individuals wanting to abandon chemotherapy in favour of dandelion root alone – though it’s likely many were seeking to supplement, not replace, their treatment. Regardless, the shift in narrative is striking. To publicly distance herself from the research after endorsing its therapeutic potential through a comprehensively evidence packed patent is difficult to interpret charitably.

Dr. Hamm has seen a clear upward trajectory in recent years, including multiple promotions, an honorary degree³⁸ and clinical leadership roles within the WE-SPARK Health Institute in recent years¹³.

Dr. Ovadje

Then: PhD student and research assistant on the dandelion root project. Pamela Ovadje won the Mitacs Award for Outstanding Innovation in 2013 for her contributions¹⁸.

Now: Dr. Ovadje has contributed content to AOR – the very company now controlling Windsor Botanical’s assets. In 2020, AOR released an “educational use only” webinar on inflammation and allergies³⁹. It was hosted by Dr. Paul Hrkal, ND – AOR’s public-facing ‘Medical Director’ – and presented by Dr. Pamela Ovadje, PhD, a cancer biochemist best known for her dandelion root extract (DRE) research¹,²,³.

The is highly unusual: Ovadje has no public research record in allergies or immunology, this seems like Ovadje is being steered into a safe, generic topic far removed from her halted oncology work. The format keeps her visible under the AOR banner, but shields her from questions about former research – an example of corporate perception management over scientific continuity. This raises further questions about whether her role was co-opted or redirected.

When Pamela Ovadje was unwittingly approached by our investigator for comment, she stated that although she is still interested in research, she is no longer involved or interested in the primary line of investigation that originally brought attention to her. This quiet withdrawal from such a groundbreaking area, without public explanation or formal closure, is notable and telling. The University itself is very open about their use of NDA’s (non-disclosure agreements) and their Intellectual property handling, alongside their corporate prioritisation⁴⁰, ⁴¹.

Heather Pratt

Then: A high-ranking university official (Executive Director of Research and Innovation) and listed director of Windsor Botanical Therapeutics during its formation phase²⁸. Notably, Pratt is listed as director of Windsor-Essex Regional Chamber of Commerce, an affiliate of WEtech Alliance and the cross-sector research initiative CUTRIC⁴², ⁴³. Pratt’s past involvement places her firmly within the broader ecosystem of Canadian biotech-industrial collaboration.

Now: As of January 2025, according to her LinkedIn profile, Heather Pratt is no longer in her role at the University of Windsor and has redirected into entrepreneurship. Her quiet departure from both the university and the research’s corporate infrastructure marks a notable shift.

This fragmentation of the original team, paired with the total absence of trial follow-through reinforces the impression of a coordinated withdrawal, reassignment, or quiet suppression of a therapy that had once promised so much.

Inverted Innovation – The University as a Gatekeeper, not a Conduit

What emerges from the Windsor dandelion root case is not merely a tale of abandoned research. It is, more profoundly, the story of an institution that appears to have inverted its role – functioning not as a public conduit for life-saving innovation, but as a gatekeeper, selectively capturing and neutralizing disruptive discoveries.

A Pattern of Containment

A breakthrough discovery is made: in this case, dandelion root extract shown to selectively induce apoptosis in cancer cells.

Publicity follows, including news coverage, awards, and community excitement.

The university encourages community donations, leveraging the public’s hope and goodwill to fund further research.

A patent is filed, and a shell company is created – ostensibly to bring the discovery to trial.

Progress halts. No human clinical trials to progress the patent. No therapeutic development. Key figures resign. The shell is transferred. Silence.

A clear pathway to a promising therapy disappears into obfuscation, displacement, and corporate opacity.

Public Money for Private Containment

Perhaps most troubling is that community donations – money from ordinary people moved by the promise of the research – appear to have been instrumental in keeping the project alive, at least in appearance.

This includes:

Named donor campaigns.

Local fundraising efforts.

Also, a continued stream of gifts documented on the university’s own website – even as the original research has gone nowhere.

This creates a deeply insidious contradiction:

The public is not only being denied access to the potential cure – they are, it seems, contributing to funding its disappearance.

In September 2024, a Windsor-based family publicly donated $30,000 CAD to Dr. Pandey’s lab to support research into Alzheimer’s disease⁴⁴. The gift was presented as a memorial tribute to Omkarnath Dhar, and the university issued a press release celebrating the donation, complete with photographs of Dr. Pandey and a group of students receiving the oversized cheque. The tone of the article was one of civic pride, gratitude, and philanthropic support for science.

With Dr. Pandey now pivoting to Alzheimer’s research, once again buoyed by large-scale donations and media optimism, the question looms:

Will the Alzheimer’s line end the same way as the dandelion root?

Is this model – hype, funding, capture, silence – now standard?

This is not merely unethical. It represents a betrayal of public trust at the deepest level:

Hope was cultivated.

Funds were accepted.

Nothing was delivered.

The pattern is not only suppressive – it’s exploitative.

If this isn’t illegal, then perhaps it should be.

The Problem of Donor Capture

Much of the early momentum behind the dandelion root project came significantly from community-driven funding. This funding was made possible by local donors – people who believed their contributions were accelerating real, lifesaving progress.

Donors such as Donna and Dave Couvillon, who made a substantial personal contribution after tragically losing their son Kevin to cancer⁴⁵. Systemically, in order for people struggling with cancer to gain access to natural treatments, there must first be human clinical trials. These trials are granted based on evidence (and rarely for natural treatments) – and in this case that is supposedly what actually happened.

Therefore, there is the question that demands an answer – what happened to the human clinical trial? the trial that was supposedly approved, the trial that could have changed the trajectory of oncology completely¹⁷, ¹⁹.

The internet is relatively quiet after the 2017 press U-turn with Dr. Hamm³⁶, ³⁷.

More recent (and potentially invalid) sources such as Politifact from 2021⁴⁶ make statements claiming that the human trial failed due to recruitment and “funding drying up,” and “difficulties in recruitment”.

However, there is

No public trial registration.

A Health Canada–approved clinical trial should have a Clinical Trial Application (CTA) number, ethics board approvals, and often a public record in a registry. None seem to exist and that’s not typical. No marketing or advertisement of said trial is discoverable either.

Recruitment failure claim

Recruiting 30 terminal patients in all of Canada over multiple years is not a difficult target if the trial was genuinely operational and there was institutional will; even extremely niche trials often recruit that many.

Funding narrative mismatch

If funding is allocated and the trial is approved, the budget typically covers the recruitment period, however long that may take. Money does not “dry up” before even enrolling, unless:

The funding wasn’t actually secured in full.

The money was redirected.

The “funding” was largely in-kind support rather than hard cash.

None of these would explanations make sense in this case context.

If publicly celebrated, donor-backed research can vanish without explanation, oversight, or results, then every other promising breakthrough must be viewed with the same scepticism. How many other discoveries have followed this same pathway? How often is philanthropic energy used to build a pipeline that ends not in public benefit, but in private stagnation?

The University of Windsor was approached with relevant questions, but our investigator was redirected without answers to a formal FOI route.

Conclusion

This report is not intended to shame or judge any one individual, but to expose a system capable of co-opting credible figures, suppressing inconvenient science, and repackaging truth into safe, marketable narratives.

A discovery with legitimate therapeutic potential – supported by local funding, developed by university researchers, and positioned for clinical trials – was transferred into private hands, redirected, and ultimately withdrawn from public view. The stated goal of delivering a novel, low-toxicity cancer treatment quietly disappeared, without explanation or accountability. This raises a troubling question: is the cancer industry structured to solve the problem, or to sustain it? The phrase “a patient cured is a customer lost” begins to feel less cynical and more descriptive of a system that thrives on chronicity rather than resolution.

It is likely that non-disclosure agreements (NDAs) are in place, effectively gagging those involved and contributing to the eerie silence around a once-promising natural cancer treatment. This pattern is consistent with the University’s broader consensus, which appears more aligned with corporate IP consolidation and industrial servitude than with public benefitting research. In an age when universities increasingly function as incubators for industry, Windsor’s approach – burying breakthrough discoveries and obscuring accountability – feels less like neglect and more like strategic concealment.

The corporate and individual patterns outlined in this report – from inactive registrations and offshore origins to the strategic repurposing of researchers and the use of credentialled figures for perception management – are not isolated anomalies. They form a clear, replicable template for how inconvenient science can be buried while maintaining the illusion of transparency and public service.

While the full network of shells and associated individuals stretches far beyond the scope of this investigation, the examples documented here are sufficient to demonstrate a consistent architecture of opacity and misdirection. To follow every thread would be to enter an endless labyrinth – and that, in itself, is part of the design.

If cures are found and then abandoned, what does that reveal about the true incentives guiding this system? Why do we continue to fund institutions that produce patents – but no treatments – while people suffer and die? The unanswered questions are not just scientific; they are deeply ethical. This is not about alleging wrongdoing, but about recognising that the current system allows important discoveries to slip into silence – simply because no mechanism exists to stop it.

References

Chatterjee SJ, Ovadje P, Mousa M, Hamm C, Pandey S. The efficacy of dandelion root extract in inducing apoptosis in drug-resistant human melanoma cells. Evid Based Complement Alternat Med. 2011;2011:129045. doi:10.1155/2011/129045. Epub 2010 Dec 30. PMID: 21234313; PMCID: PMC3018636. Available from: https://pubmed.ncbi.nlm.nih.gov/21234313
Ovadje P, Chochkeb M, Akbari-Asl P, Hamm C, Pandey S. Selective induction of apoptosis and autophagy through treatment with dandelion root extract in human pancreatic cancer cells. Pancreas. 2012 Oct;41(7):1039-47. doi:10.1097/MPA.0b013e31824b22a2. PMID: 22647733. Available from: https://pubmed.ncbi.nlm.nih.gov/22647733
Ovadje P, Ammar S, Guerrero JA, Arnason JT, Pandey S. Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways. Oncotarget. 2016 Nov 8;7(45):73080-100. doi:10.18632/oncotarget.11485. PMID: 27564258; PMCID: PMC5341965. Available from: https://pubmed.ncbi.nlm.nih.gov/27564258
University of Windsor. Student researchers inspired by legacy of cancer patient [Internet]. Windsor (ON): University of Windsor; 2012 Feb 22 [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/dailynews/2012-02-22/student-researchers-inspired-by-legacy-of-cancer-patient. Archived at: https://web.archive.org/web/20250731135241/https://www.uwindsor.ca/dailynews/2012-02-22/student-researchers-inspired-by-legacy-of-cancer-patient
Pandey S, et al. Medicament containing Taraxacum plant root extract for treatment or prevention of cancer, and method for preparing same. United States patent US10179156B2. 2019. Available from: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10179156
Corporations Canada. Windsor Botanical Therapeutics Inc. – Federal Corporation Profile [Internet]. Ottawa (ON): Government of Canada; 2025 [cited 2025 Aug 5]. Available from: https://federalcorporation.ca/corporation/8963673
Alberta Corporations. Advanced Orthomolecular Research Inc. – company history and dissolution [Internet]. Edmonton (AB): Alberta Corporations; [cited 2025 Aug 5]. Available from: https://albertacorporations.com/advanced-orthomolecular-research-inc#history
AOR Distribution. Buy nutritional supplements – UK and Europe [Internet]. [place unknown]: AOR Distribution; [cited 2025 Aug 5]. Available from: https://www.aordistribution.co.uk. Archived at: https://web.archive.org/web/20250801222003/https://www.aordistribution.co.uk
Companies House. SUPPLEMENTS PLUS LTD – company overview [Internet]. London: Companies House; [cited 2025 Aug 5]. Available from: https://find-and-update.company-information.service.gov.uk/company/10646053

Companies House. A.O.R. (Europe) Limited – company overview [Internet]. London: Companies House; [cited 2025 Aug 5]. Available from: https://find-and-update.company-information.service.gov.uk/company/05190679
University of Windsor. UWin researcher on a roll using natural extracts to fight cancer [Internet]. Windsor (ON): University of Windsor; 2014 Nov 26 [cited 2025 Aug 7]. Available from: https://www.uwindsor.ca/dailynews/2014-11-26/uwindsor-researcher-roll-using-natural-extracts-fight-cancer
University of Windsor. Dr. Sivaram Pandey: Department of Chemistry and Biochemistry [Internet]. Windsor (ON): University of Windsor; 2016 [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/kinesiology/505/dr-siyaram-pandy-department-chemistry-biochemistry-university-windsor-complex-natural-extract
WeSPARK Health. Dr. Caroline Hamm [Internet]. Windsor (ON): WeSPARK Health; [cited 2025 Aug 7]. Available from: https://www.wesparkhealth.com/researchers-5/dr-caroline-hamm
Hamm C, Kanjeekal S, Gupta R, Ng W. Dandelion root and chronic myelomonocytic leukaemia. Blood. 2013;122(21):5216. doi:10.1182/blood.V122.21.5216.5216. Available from: https://www.researchgate.net/publication/336466928_Dandelion_Root_and_Chronic_Myelomonocytic_Leukemia
Google Patents. Patent: CA2868383C – dandelion extract for cancer [Internet]. Ottawa (ON): Government of Canada; 2013 [cited 2025 Aug 5]. Available from: https://patents.google.com/patent/CA2863838C/en
Google Patents. Patent: IN2014KN01586A – cancer treatment extract [Internet]. Ottawa (ON): Government of Canada; 2014 [cited 2025 Aug 5]. Available from: https://patents.google.com/patent/IN2014KN01586A/en
Thompson C. Dandelion research enters clinical trials [Internet]. Windsor (ON): Windsor Star; 2015 Feb 18 [cited 2025 Aug 5]. Available from: https://www.pressreader.com/canada/windsor-star/20150218/282256663934809
Thompson C. Dandelion cancer treatment leads to award [Internet]. Burnaby (BC): Mitacs; 2015 Nov 24 [cited 2025 Aug 5]. Available from: https://www.mitacs.ca/news/windsor-star-dandelion-cancer-treatment-research-leads-to-award/#:-:text=Reading%20Time%2020%20minutes,respond%20positively%20%C2%80%9D%20said%20Ovadje
University of Windsor. Human clinical trials on for cancer-killing dandelion extract [Internet]. Windsor (ON): University of Windsor; 2015 Feb 18 [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/dailynews/2015-02-18/human-clinical-trials-cancer-killing-dandelion-extract
CBC News. Dandelion tea touted as possible cancer killer. 2012 Feb 16. Available from: https://www.cbc.ca/news/canada/windsor/dandelion-tea-touted-as-possible-cancer-killer-1.1129321

CBC News. 30 patients to test dandelion’s cancer-killing potential [Internet]. Toronto (ON): CBC News; 2017 Jan 27 [cited 2025 Aug 6]. Available from: https://www.cbc.ca/news/canada/windsor/30-patients-to-test-dandelion-s-cancer-killing-potential-1.2959815
University of Windsor. BE Symposium: speaker profiles – Joseph Elliott [Internet]. Windsor (ON): University of Windsor; [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/besymp/315/speakers?utm
Corporations Canada. Windsor Botanical Therapeutics – Corporation Number: 8963673. 15^th March 2018. Available at: https://ised-isde.canada.ca/cc/lgcy/fdrlCrpDtls.html?p=0&corpId=8963673&crpNm=&crpNmbr=8963673&bsNmbr=&cProv=&cStatus=&cAct=
Journal of Alzheimer’s Disease. Member profile: Dr. Sivaram Pandey [Internet]. Amsterdam: IOS Press; 2017 [cited 2025 Aug 5]. Available from: https://www.j-alz.com/members/2694?utm
Hybrid Electric Vehicle Powertrain Design & Development. Heather Pratt – University of Windsor [Internet]. Windsor (ON): 2016 [cited 2025 Aug 5]. Available from: https://hevpdd.ca/members/heather-pratt/?utm
Companies House. Traj Nibber – director appointments [Internet]. London: Companies House; [cited 2025 Aug 5]. Available from: https://find-and-update.company-information.service.gov.uk/officers/pZJBsaMk1gnYw67fKdpfEoI0jBg/appointments
Companies House. Pramjit Kaur Nibber – director appointments [Internet]. London: Companies House; [cited 2025 Aug 5]. Available from: https://find-and-update.company-information.service.gov.uk/officers/JZIbILgT4Q9vwPQOJxvXbMDKlK8/appointments
HK Corporation Search. Corporate listing: Windsor Botanical Therapeutics – director records (Canada) [Internet]. Hong Kong: HK Corporation Search; [cited 2025 Aug 5]. Available from: https://canada.hkcorporationsearch.com/companies/hsjgehds/
Windsor Botanicals. Windsor Botanicals official website [Internet]. [place unknown]: Windsor Botanicals; [cited 2025 Aug 5]. Available from: https://www.windsorbotanicals.com/
Companies House. SUPPLEMENTS PLUS LTD – company overview [Internet]. London: Companies House; [cited 2025 Aug 5]. Available from: https://find-and-update.company-information.service.gov.uk/company/10646053
Government of Canada. Federal corporation information – TRAJPAM Investment Ltd. [Internet]. Ottawa (ON): Government of Canada; [cited 2025 Aug 9].Available from: https://ised-isde.canada.ca/cc/lgcy/fdrlCrpDtls.html?p=0&corpId=7930348&crpNm=Trajpam%20Investment%20Ltd.&crpNmbr=&bsNmbr=&cProv=&cStatus=&cAct=
Advanced Orthomolecular Research (AOR). Research collaborations – clinical trial partnerships including Dr Caroline Hamm [Internet]. Calgary (AB): AOR Canada Inc.; [cited 2025 Aug 5]. Available from: https://aor.ca/research-collaborations/
NutraIngredients-USA. The Canadian edge: in conversation with AOR CEO Dr Traj Nibber [Internet]. 2019 Apr 4 [cited 2025 Aug 5]. Available from: https://www.nutraingredients-usa.com/Article/2019/04/04/The-Canadian-edge-In-conversation-with-AOR-CEO-Dr-Traj-Nibber/
Advanced Orthomolecular Research (AOR). MyBlueprint™ [Internet]. Calgary (AB): AOR Canada Inc.; [date unknown] [cited 2025 Aug 9]. Available from: https://aor.ca/myblueprint
University of Windsor. 2020 donor support for Dr. Sivaram Pandey [Internet]. Windsor (ON): University of Windsor; 2020 Jul 27 [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/supportuwindsor/2020-07-27/example-news-article-4
University of Windsor. Sivaram Pandey news, awards, and research coverage [Internet]. Windsor (ON): University of Windsor; September 30^th 2024 [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/dailynews/tags/siyaram-pandey
Caton M. False internet claims about cancer cure trouble local oncologist [Internet]. Windsor (ON): Windsor Star; 2017 Feb 8 [cited 2025 Aug 6]. Available from: https://windsorstar.com/news/local-news/false-internet-claims-about-cancer-cure-trouble-local-oncologist
CBC Radio. How a Canadian doctor’s study on dandelion tea became fake news fodder [Internet]. Toronto (ON): CBC Radio; 2016 Nov 4 [cited 2025 Aug 6]. Available from: https://www.cbc.ca/radio/whitecoat/why-fake-news-is-bad-for-your-health-1.4423628/how-a-canadian-doctor-s-study-on-dandelion-tea-became-fake-news-fodder-1.4427348
University of Windsor. University to honour physician and scholar [Internet]. Windsor (ON): University of Windsor; 2022 Oct 12 [cited 2025 Aug 6]. Available from: https://www.uwindsor.ca/dailynews/2022-10-07/university-honour-physician-and-scholar
Ovadje P. Inflammation and allergies [Internet]. Calgary (AB): AOR Inc.; 2020 Mar 24 [cited 2025 Aug 9]. Available from: https://aor.ca/all-media/inflammation-and-allergies/
University of Windsor. Statement on intellectual property and use of NDAs [Internet]. Windsor (ON): University of Windsor; [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/research-partnerships/306/intellectual-property
University of Windsor. Inventors’ handbook [Internet]. Windsor (ON): University of Windsor; 2018 [cited 2025 Aug 5]. Available from: https://www.uwindsor.ca/research-partnerships/sites/uwindsor.ca.research-partnerships/files/university_of_windsor_inventors_handbook_2018.pdf
Federal Corporation. Director profile: Heather Pratt [Internet]. Ottawa (ON): Government of Canada; [cited 2025 Aug 5]. Available from: https://federalcorporation.ca/director/heather-pratt
Federal Corporation. Corporation profile: Windsor Botanical Therapeutics Inc. (Heather Pratt listed as director) [Internet]. Ottawa (ON): Government of Canada; [cited 2025 Aug 5]. Available from: https://federalcorporation.ca/corporation/8968756
University of Windsor. Sivaram Pandey – Daily News Archive [Internet]. Windsor (ON): University of Windsor; September 20^th 2024 [cited 2025 Aug 6]. Available from: https://www.uwindsor.ca/dailynews/tags/siyaram-pandey
Thompson C. Dandelion root cancer treatment enters clinical trials; company to market it formed [Internet]. Windsor (ON): Windsor Star; 2015 Feb 17 [cited 2025 Aug 7]. Available from: https://windsorstar.com/news/dandelion-root-cancer-treatment-enters-clinical-trials-company-to-market-it-formed
PolitiFact. Fact-checking claim that dandelion root extract is a cancer killer [Internet]. St. Petersburg (FL): Poynter Institute; 17 Jun 2021 [cited 2025 Aug 9]. Available from: https://www.politifact.com/factchecks/2021/jun/17/instagram-posts/fact-checking-claim-dandelion-root-extract-cancer-/?